Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL579236 | 0.76 | — | — | |
| SCHEMBL8394151 | 0.67 | — | — | |
| SCHEMBL17176658 | 0.67 | — | — | |
| SCHEMBL29157377 | 0.67 | NLRP3 (0.32) | NLRP3 | |
| Hydrochloric Acid SCHEMBL21060168 | 0.65 | — | — | |
| SCHEMBL2782157 | 0.64 | KDM4E (0.32) | NLRP3 | |
| SCHEMBL21798362 | 0.63 | HTR5A (0.30) | — | |
| SCHEMBL21798392 | 0.63 | TRPA1 (0.32) | — | |
| SCHEMBL25541952 | 0.63 | CYP2D6 (0.33) | — | |
| SCHEMBL12709934 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| CN-116332816-A | Method for preparing 1-mercaptomethyl cyclopropylacetic acid by one-step method | 江苏阿尔法药业股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2021-07-27 | — | — | US | disclosed |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2021-07-27 | — | — | US | disclosed |
| EP-3849979-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | Novartis AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| CN-112996789-A | Antiviral pyridopyrazinedione compounds | 诺华股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2020053654-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| US-20200079772-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | NLRP3 404/4885 |
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | ZC3HAV1, IL5, TYMP | NLRP3 404/4885 |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | NLRP3 404/4885 |
| US-20200079772-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | ZC3HAV1, IL5, TYMP | NLRP3 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.